Compounds > 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Substance Withdrawal Syndrome

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Substance Withdrawal Syndrome in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ebert, D; Hesslinger, B; Juengling, FD; Klein, T; Lohrmann, C; van Elst, LT1
Booij, J; Franken, IH; van den Brink, W; Zijlstra, F1
Ferrari, MD; Saxena, PR; van Royen, EA; Verhoeff, NP; Visser, WH1
Seeman, P; Tallerico, T1

Other Studies

4 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Substance Withdrawal Syndrome

ArticleYear
Different striatal dopamine D2 receptor occupancy in alcohol dependent patients with or without physical withdrawal symptoms --a study using IBZM-SPECT.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:9

    Topics: Adult; Alcohol-Induced Disorders, Nervous System; Benzamides; Binding Sites; Binding, Competitive; Dopamine; Dopamine Antagonists; Ethanol; Humans; Male; Middle Aged; Neostriatum; Neurons; Pyrrolidines; Radioligand Assay; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Tomography, Emission-Computed, Single-Photon

2002
Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:4

    Topics: Adult; Benzamides; Cues; Data Interpretation, Statistical; Dopamine; Heroin Dependence; Humans; Male; Middle Aged; Neostriatum; Psychiatric Status Rating Scales; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Smoking; Substance Abuse Detection; Substance Withdrawal Syndrome; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2008
Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?
    Cephalalgia : an international journal of headache, 1993, Volume: 13, Issue:5

    Topics: Benzamides; Blood-Brain Barrier; Brain; Contrast Media; Dopamine D2 Receptor Antagonists; Ergotamine; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Migraine Disorders; Pyrrolidines; Receptors, Dopamine D2; Substance Withdrawal Syndrome; Substance-Related Disorders; Tomography, Emission-Computed, Single-Photon

1993
Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    The American journal of psychiatry, 1999, Volume: 156, Issue:6

    Topics: Animals; Antipsychotic Agents; Benzamides; Brain; Carbon Radioisotopes; Cloning, Molecular; Clozapine; Dibenzothiazepines; Dopamine; Dose-Response Relationship, Drug; Humans; Iodine Radioisotopes; Mice; Pyrrolidines; Quetiapine Fumarate; Raclopride; Radionuclide Imaging; Receptors, Dopamine D2; Salicylamides; Spodoptera; Substance Withdrawal Syndrome; Tritium

1999